Search results
Semaglutide Reduced Risk for Major Kidney Disease Events by 24% for Patients with Type 2 Diabetes...
Benzinga· 53 minutes agoToday, findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 (glucagon-like peptide-1) receptor agonist were reported, demonstrating ...
New Weight-Loss Drugs and Devices Are Coming This Week
Barrons.com· 6 days agoWeight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American...
Penobscot County Moms at Risk: Sharp Rise in Blood Pressure During Pregnancy Uncovered. Dr. Explains
Fox Bangor· 6 days agoIn this article, Dr. Adriana Davis, DO, Family Medicine, shares her expert insights of the findings...
Structural basis of tolvaptan binding to the vasopressin V2 receptor - Acta Pharmacologica Sinica
Nature· 4 days agoThe vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD), with tolvaptan being the first ...